Profilnine, Profilnine HP, Profilnine HT, Profilnine SD Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The profilnine, profilnine HP, profilnine HT, and profilnine SD market research report is one of a series of new reports that provides profilnine, profilnine HP, profilnine HT, and profilnine SD market statistics, including profilnine, profilnine HP, profilnine HT, and profilnine SD industry global market size, regional shares, competitors with a profilnine, profilnine HP, profilnine HT, and profilnine SD market share, detailed profilnine, profilnine HP, profilnine HT, and profilnine SD market segments, market trends and opportunities, and any further data you may need to thrive in the profilnine, profilnine HP, profilnine HT, and profilnine SD industry. This profilnine, profilnine HP, profilnine HT, and profilnine SD market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of rare diseases, expanding use of Factor IX in non-hemophilia therapies, growing demand for long-acting factor IX therapies, increasing focus on patient-centric care, and growing disposable income. Major trends in the forecast period include the development of recombinant DNA technology, advancements in cryopreservation, automation in plasma processing, the development of mini pool fractionation technology, and the development of the pathogen inactivation process.

The increasing diagnosis of bleeding disorders is expected to drive the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market in the coming years. Bleeding disorders, such as hemophilia, von Willebrand disease, and platelet function disorders, are conditions that impair the blood's ability to clot, leading to excessive bleeding. This rise in diagnoses is attributed to advancements in diagnostic technologies, better access to healthcare services, and expanded genetic screening and testing capabilities. Profilnine is used to treat bleeding disorders, especially hemophilia B, by providing clotting factor IX replacement to help control and prevent bleeding episodes. For example, in November 2022, the United Kingdom Haemophilia Centre Doctors’ Organization reported that new registrations of Hemophilia A in the UK rose from 16 in 2021 to 19 in 2022. As a result, the growing number of bleeding disorder diagnoses is contributing to the growth of the Profilnine market.

The rising aging population is also expected to fuel the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market. This demographic shift is driven by factors such as longer life expectancy, declining birth rates, and advancements in healthcare that contribute to improved longevity. As the population ages, there is an increased need for therapies such as Profilnine to manage bleeding disorders, such as hemophilia B, by replacing clotting factor IX and reducing the risk of bleeding. According to statistics published by the Population Reference Bureau in January 2024, the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase. Their share of the overall population will also grow from 17% to 23%. Therefore, the growing aging population is helping to drive the market for Profilnine.

Increased healthcare expenditure is another factor expected to accelerate the growth of the Profilnine, Profilnine HP, Profilnine HT, and Profilnine SD market. Healthcare expenditure refers to the total financial resources spent on medical services, infrastructure, pharmaceuticals, and other healthcare-related activities. It is rising due to factors such as higher operational costs in healthcare facilities, the increasing prevalence of chronic and lifestyle-related diseases, a rise in genetic disorders, medical advancements, and greater access to healthcare services. The growing healthcare expenditure supports the management of bleeding disorders by funding clotting factor IX replacement therapies, ultimately improving patient outcomes and reducing hospitalization costs. For example, a report from the UK Office for National Statistics in May 2024 revealed a 5.6% rise in total healthcare expenditure from 2022 to 2023, compared to a 0.9% increase the previous year. Additionally, long-term health and social care expenditure rose by 2.8% in real terms in 2022. As healthcare spending continues to rise, it boosts access to treatments such as Profilnine, further driving the market’s growth.

The key company operating in the profilnine, profilnine HP, profilnine HT, profilnine SD market is Grifols S.A.

North America was the largest region in the profilnine, profilnine HP, profilnine HT, profilnine SD market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in profilnine, profilnine HP, profilnine HT, profilnine SD report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the profilnine, profilnine HP, profilnine HT, profilnine SD market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Profilnine is a plasma-derived concentrate of human coagulation factor IX, designed to treat and prevent bleeding in individuals with hemophilia B. This genetic disorder results from a deficiency in factor IX, impairing the blood’s ability to clot. By temporarily boosting factor IX levels in the bloodstream, Profilnine helps restore clotting ability and effectively manages bleeding episodes. In addition to factor IX, it contains small amounts of other clotting factors, such as factors II, VII, and X.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Profilnine, along with its variants Profilnine HP, Profilnine HT, and Profilnine SD, is primarily indicated for hemophilia B, surgical procedures, and trauma management. Hemophilia B is a genetic condition where the body lacks enough factor IX for proper blood clotting. Profilnine replenishes this factor, minimizing the risk of excessive bleeding. The product is available through hospital pharmacies, retail pharmacies, and online platforms, and is used in various settings including hospitals, clinics, and home care environments.

The profilnine, profilnine HP, profilnine HT, profilnine SD market consist of sales of factor IX concentrate, administration kits, and dilution agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.